The bipolar depression treatment market is expected to grow positively through 2036, with the United States accounting for the largest share compared to EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Bipolar depression has the highest prevalence among diagnosed cases in the US within the 18-25 age group, affecting approximately 3.40% of this population.
Current pharmacological treatment primarily involves mood stabilizers like lithium and valproate, along with atypical antipsychotics such as quetiapine, lurasidone, and the olanzapine/fluoxetine combination. Approved treatments include FANAPT, marketed by Vanda Pharmaceuticals, and VRAYLAR, marketed by AbbVie. However, substantial unmet needs persist due to suboptimal response, delayed diagnosis, and poor long-term adherence, while current therapies present safety concerns including metabolic and cognitive side effects.
Emerging Therapies in Development
Several promising bipolar depression therapies are advancing through clinical trials. Azetukalner, an oral modulator of Kv7 potassium channels developed by Xenon Pharmaceuticals, aims to stabilize excessive neuronal activity without causing mania or common antipsychotic side effects. Autobahn Therapeutics’ ABX-002 is an orally administered, brain-targeted thyroid hormone beta receptor agonist intended to act specifically within neural regions linked to depression. AbbVie’s ABBV-932 is a selective modulator of the D3 dopamine receptor being developed for bipolar disorder and generalized anxiety disorder.
Alto Neuroscience’s ALTO-100 is designed to enhance neuroplasticity within the hippocampus for mood regulation and cognition, currently in Phase 2b trials as an adjunctive therapy for bipolar depression. NRx Pharmaceuticals’ NRX-101 is a proprietary oral combination of D-cycloserine and lurasidone, and would represent the first treatment regimen specifically designed for severe bipolar depression in patients experiencing acute suicidal thoughts or behaviors if cleared by regulators.
Recent developments show that in January 2026, Autobahn Therapeutics reported topline results from the Phase II AMPLIFY-BD trial evaluating adjunctive azetukalner in bipolar depression are expected in the second quarter of 2026. Additionally, the Phase III X-CEED study evaluating azetukalner in patients with bipolar depression I or II is underway as reported at the JP Morgan Healthcare Conference.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.prnewswire.com/news-releases/bipolar-depression-market-expected-to-witness-accelerated-expansion-during-the-forecast-period-20262036-amid-advancements-in-psychiatric-therapies—delveinsight-302710457.html